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Abstract
The wide dissemination of carbapenemase-producing Gram-negatives (CPGNs), including enterobacterial species and non-fermenters,
has caused a public health crisis of global dimensions. These organisms cause serious infections in hospitalized patients, and are associ-
ated with increased mortality. Cross-transmission is common, and outbreaks may occur in healthcare facilities where the infection con-
trol practices are inadequate. CPGNs exhibit extensive drug-resistant phenotypes, complicate therapy, and limit treatment options.
Systematic data on therapy are limited. However, regimens combining two or more active agents seem to be more efﬁcacious than
monotherapy in carbapenemase-producing Klebsiella pneumoniae infections. Strict infection control measures, including active surveillance
for timely detection of colonized patients, separation of carriers from non-carriers, and contact precautions, are of utmost importance,
and may be the only effective way of preventing the introduction and transmission of these bacteria in healthcare settings.
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Introduction
Carbapenemase-producing Gram-negatives (CPGNs) have
become a major concern worldwide [1,2]. Many factors,
including the ease of international travel for medical tourism
and migration, and the importation of food products, have
been responsible for introducing these microorganisms to
several countries far beyond their country of origin [3,4].
The extensive dissemination of carbapenemase-producing
Klebsiella pneumoniae (CPKP) and, to a lesser extent, other
clinically important carbapenemase-producing Enterobacteria-
ceae (CPE), such as Escherichia coli, has caused serious thera-
peutic problems that parallel the methicillin-resistant
Staphylococcus aureus crisis two decades ago. In fact, a recent
European trend analysis predicted that the number of blood-
stream infections (BSIs) caused by third-generation cephalo-
sporin-resistant E. coli are likely to surpass the number of
methicillin-resistant Staphylococcus aureus BSIs in the near
future [5]. K. pneumoniae, since its integration into the noso-
comial ﬂora in the early 1970s, consistently remains among
the pathogens frequently involved in hospital-acquired infec-
tions. A characteristic trait of the species is its ability to
acquire and maintain multidrug resistance plasmids, such as
those encoding extended-spectrum b-lactamases, along with
other resistance determinants. Today, K. pneumoniae has
become the main reservoir of diverse plasmid-borne bla
genes coding for the so-called carbapenemases, i.e. b-lacta-
mases that hydrolyse almost all available b-lactams, including
carbapenems, the most important being the KPCs and the
metallo-b-lactamases (MBLs) VIM, IMP, and NDM [2,6,7]. It
should be noted at this point that the term ‘carbapenemase’
reﬂects the clinical impact of carbapenem hydrolysis rather
than a genuine preference of these enzymes for carbapenems
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over other b-lactam substrates. The spread of CPKPs has
reached epidemic proportions in various areas, such as some
southern European countries, the north-eastern USA, the
Indian subcontinent, and the Far East [2]. CPE isolates are
invariably multidrug-resistant, carrying a wide variety of addi-
tional acquired determinants that mediate resistance to am-
inoglycosides as well as other clinically less important
antimicrobials, such as co-trimoxazole, chlorampenicol, and
nitrofurantoin [1]. Moreover, high-level resistance to ﬂuori-
nated quinolones is commonly seen among these isolates,
especially in CPKPs.
This article reviews the risk factors related to coloniza-
tion, infection and mortality caused by CPGNs. Available
in vitro and in vivo data are discussed in relation to the treat-
ment of infections caused by these bacteria. Also, special
emphasis is placed on reviewing infection control measures
to prevent the spread of CPGNs.
Risk Factors for Colonization
Colonization prior to infection has usually been detected in
the gastrointestinal tract (GIT) [8,9]; however, other sites,
including the respiratory tree, surgical sites, and the urinary
tract, are also commonly colonized [10–12].
Several risk factors have been identiﬁed for colonization
with CPGNs (Table 1). The risk factors described in the lit-
erature may vary for different Gram-negative bacteria and
also for the type of enzyme [9,12,13,15–18] (also see the
section below, ‘Measures required for controlling the spread
of carbapenemase producers’). However, it should be noted
that most of these studies on risk factors and outcome of
infection were of the retrospective, case–control or cohort
type, with small sample sizes. Study populations were usually
mixed (intensive-care unit (ICU) and non-ICU settings) with
varying lengths of follow-up.
In a recent cross-sectional survey [13], extended stay in
hospital, staying with a colonized patient in the same room
and a high number of known carriers in the ward were inde-
pendent risk factors for carbapenem-resistant K. pneumoniae
(CRKP) carriage. The results of a nested case–control study
in the same paper showed that antibiotic exposure within
the previous 3 months and colonization with other resistant
pathogens were related to the carriage. Antibiotic exposure
within the previous 3 months, receipt of co-amoxiclav and
screening within 3 months of the ﬁrst CRKP-positive culture
were predictors of continued CRKP colonization.
In another study, persistent carriage was documented in
patients who were transferred from another healthcare facil-
ity, had used ﬂuoroquinolones previously, and were admitted
within the last 3 months since the ﬁrst carbapenem-resistant
Enterobacteriaceae (CRE) isolation [9].
Types of Clinical Infection and Related Risk
Factors
A wide spectrum of clinical infections are caused by CPGNs,
and include primary or catheter-related bacteraemia [19–21],
nosocomial pneumonia, including ventilator-associated cases
[10,20,22], surgical site and wound infections [17,20], perito-
nitis [20], endocarditis [23], mediastinitis [24], and urinary
tract infections [20]. Outbreaks have frequently been
reported with CPKP [12,20,25–27], but also with other en-
terics and non-fermentatives [27].
Risk factors for infection include advanced age, severe
underlying disease with high APACHE-II scores, mechanical
ventilation [28], organ or stem cell transplantation [28,29],
and extended stay in hospital [28]. Previous antibiotic use is
almost always present as an independent risk factor for
infection with these bacteria. Although prior use of carba-
penems is a frequent culprit [21], use of any other antibiot-
ics, including quinolones, b-lactamase inhibitor combinations,
cephalosporins, and glycopeptides, have also been detected
in the recent history of patients [24,28,30].
Analysis of 28 patients with VIM-1-producing K. pneumoniae
(VPKP) bacteraemia in two Greek hospitals showed that youn-
ger age, multiple trauma, admission to an ICU, extended hospi-
tal stay and previous therapy with carbapenems, quinolones or
cephalosporins were related risk factors. However, in multivari-
ate analysis, none of these factors remained signiﬁcant [31].
However, the same group later reported on a comparison of
67 patients with VPKP bacteraemia with 111 patients with non-
VPKP infection, and found that prior exposure to more than
three different classes of antibiotic, being in an ICU and prior
use of carbapenems were signiﬁcant independent predictors for
infection [21]. During an outbreak with CRKP in a Puerto Rican
Hospital, transfer between units, wounds and surgery were
found to be independent risk factors for CRKP infection [17].
TABLE 1. Risk factors for colonization with carbapenemase-
producing Gram-negatives [8,13,14]
Prior exposure to or current use of antibiotics
Use of a ﬂuoroquinolone
Malignancy
Poor functional status
Non-surgical invasive procedure
Extended stay in hospital
Admission to intensive-care unit
Admission to post-acute-care units
Sharing a room with a known carrier
Diaper use
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A case–control study in two Brazilian hospitals with 86
patients infected with MBL-producing Pseudomonas aeruginosa
(MBL-PA) and 212 controls infected with non-MBL-PA found
that exposure to quinolones or b-lactams, underlying neuro-
logical disease, presence of urinary tract infection and renal
failure were independent risk factors for acquistion of MBL-
PA infection [32].
Risk Factors for Outcome and Mortality
High mortality rates have been reported for infections
caused by CPGNs. Rates for attributable mortality (i.e.
where the presence of CPGN infection contributed signiﬁ-
cantly to the mortality) ranged between 51.2% and 95% for
carbapenem-resistant P. aeruginosa infections [2,33] and
between 18.9% and 48.0% for CRE infections [12,19,28].
Several independent risk factors for mortality have been
identiﬁed (Table 2). Daikos et al. [19] reported that patients
infected with VPKP exhibiting resistance to carbapenems
(MIC >4 mg/L) had signiﬁcantly higher mortality than those
infected with carbapenem-susceptible VPKP (MIC £4 mg/L)
or non-VPKP (all-cause 14-day mortality rates were 42.9%
vs. 18.9% vs. 14.8, respectively). The effect of carbapenem
resistance on mortality was probably mediated by the failure
to provide effective antimicrobial therapy. VIM production
had no effect on mortality.
Higher mortality rates were also detected for infections
caused by MBL-PA than for those caused by non-MBL-PA
(51.2% vs. 32.1%, respectively) by crude comparison. Mortal-
ity per 1000 patient-days also increased (17.3 days vs.
11.8 days, respectively) with MBL-PA. Multivariate analysis
indicated that severe sepsis or septic shock and shorter
usage of appropriate therapy for £72 h were signiﬁcantly
associated with increased mortality [33].
A literature review found that the crude mortality rate
for CPE infections was 58.7% in patients with solid organ
transplantation, and six of seven patients with liver transplan-
tation succumbed to infection with these bacteria [34].
In a retrospective cohort study in which 42% of patients
had undergone solid organ transplantation and had bactera-
emia with CRKP, 42% died at 30 days. Lack of microbiologi-
cal eradication at 7 days was independently associated with
30-day mortality. A favourable clinical outcome was associ-
ated with adjunctive procedures performed for removal of
the source of infection and microbiological clinical response
at 7 days. Survival was not improved with early therapy and
use of antibiotics that are active in vitro [29].
Patel et al. [28] reported that CRKP-infected patients died
more frequently during hospitalization than those infected
with carbapenem-sensitive K. pneumoniae (48% vs. 20%,
respectively, p <0.001). Infection-related mortality was also
signiﬁcantly higher (38% vs. 12%, p <0.001) in patients with
CRKP infections. Source control favoured better outcome,
whereas timely administration of antibiotics that er active
in vitro did not alter the mortality rate.
Schwaber et al. [8] found that CRKP isolation predicted
death signiﬁcantly after adjustment for severity of illness in a
group of patients with K. pneumoniae clinical isolates (48
patients with CRKP vs. 56 with carbapenem-sensitive
K. pneumoniae) and 59 control patients without K. pneumo-
niae isolation.
Treatment Options
Most of the data published in the literature on therapy have
been related to CPKP; systematic data on the treatment of
infections caused by other CPGNs are still scarcely available.
In vitro data
The most active antibacterial agents against CPE with either
KPCs or MBLs are colistin, tigecycline, and fosfomycin, the
former two being widely used for treatment of the respec-
tive infections. However, as shown in recent studies, selec-
tion of colistin-resistant and tigecycline-resistant mutants is
increasing [35–38]. Clinical experience with the use of fosfo-
mycin against CPE is limited [39], but the drug is known for
its ability to readily select for resistance [40]. Among amino-
glycosides, gentamicin has partly retained its in vitro efﬁcacy
against KPC and VIM producers (most NDM producers are
resistant to all aminoglycosides, owing to production of 16S
rRNA methylases). For carbapenems, these organisms gener-
ally have elevated MICs, but some isolates exhibit low MIC
values despite the production of a carbapenemase. However,
classiﬁcation of a given CPE as carbapenem-susceptible may
differ, depending on the use of either the CLSI recommenda-
tions [41] or the EUCAST recommendations (2012; http://
www.eucast.org]. The issue is of clinical importance, as a
TABLE 2. Risk factors for mortality in patients infected with
carbapenemase-producing Gram-negatives [7,8,12,19,28,29,
33,34]
Older age
Severity of underlying disease
Malignancy
Mechanical ventilation
Solid organ transplantation
Severe sepsis and/or septic shock
Carbapenem resistance
Inappropriate antibiotic therapy
Short duration (£72 h) of appropriate antibiotic therapy
Lack of microbiological eradication at 7 days
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meaningful proportion of CPEs characterized as resistant
according to CLSI interpretive criteria appear susceptible by
the criteria of EUCAST, which has adopted higher carbape-
nem breakpoints. Of the remaining b-lactams, aztreonam,
although not hydrolysable by MBLs, is of limited usefulness,
as MBL-positive isolates frequently coexpress extended-spec-
trum b-lactamases.
Attempts have also been made to reveal potential synergism
with several combinations of antimicrobial agents, commonly
including colistin, by the use of time-kill experiments. Despite
some conﬂicting results and the inherent limitations of this
methodology, time-kill studies have indicated synergistic
effects of colistin with various antibiotics, including tigecycline,
carbapenems, rifampin, and doxycycline, against CPKP [42–
44]. Also, combinations of colistin, meropenem or gentamicin
with fosfomycin appear to be synergistic and partly prevent
the selection of CPKP variants that are resistant to the latter
agent [45]. It is of note that in vitro models simulating human
pharmacokinetics suggest that carbapenems in optimized dos-
ing regimens, either alone or in combination with tigecycline,
may cause, within 24–48 h, a signiﬁcant, although transient,
reduction in the viable counts of KPC-producing K. pneumo-
niae, including isolates resistant to carbapenems [46].
Animal models
Experimental infections in several animal models have also
been used to evaluate the efﬁcacy of carbapenems. Given
the magnitude of the problem caused by CPKPs, the number
of these studies is remarkably small. Moreover, the therapeu-
tic potential of colistin and tigecycline, which have become
ﬁrst-line antibiotics against CPKP infections, has not been
assessed adequately in animal models. Nevertheless, the rele-
vant studies have produced some interesting results indicat-
ing that carbapenems have their place in the treatment of
CPKP infections. In the neutropenic murine thigh infection
model, imipenem (60 mg/kg every 2 h) exhibited a signiﬁcant
bactericidal effect against VIM producers, with MICs of 2 and
4 mg/L (estimated T>MIC of 40%) [47]. With the same
model and dosing scheme, meropenem has been found to be
more effective (L. Tzouvelekis, unpublished data). Imipenem,
meropenem, ertapenem and aztreonam have also been found
to be efﬁcacious against a carbapenem-susceptible, VIM-posi-
tive E. coli isolate in a rabbit peritoneal abscess model [48].
Similarly, doripenem has shown signiﬁcant therapeutic poten-
tial in experimental infections caused by KPC-producing
K. pneumoniae isolates, with MICs of up to 8 mg/L in both
immunocompetent and neutropenic mice [49]. An ertape-
nem–doripenem combination has also been tested against
KPC-producing K. pneumoniae in an immunocompetent mur-
ine thigh infection model, based on the notion that the high
afﬁnity of KPC for ertapenem would ‘trap’ the enzyme, thus
facilitating the activity of doripenem. The relevant experi-
mental data seem to support this interesting concept [50].
Clinical experience from a high-prevalence area
It is arguable whether reviewing the studies reporting on the
efﬁcacy of various antibiotic regimens for CPKP infections
could lead to solid conclusions for optimal therapeutic
approaches, as it is not possible to measure and adjust for
various confounding factors that may affect patient outcome.
On the other hand, it is unlikely that residual confounding
could have signiﬁcant impact on the results, given that CPKP
usually affects patients who have common characteristics.
Data from nine relevant studies conducted during 2004–2011
in Greek hospitals included 234 patients for whom adequate
clinical information, the efﬁcacy of the antimicrobial treatment
and the susceptibility status of the infecting CPKP isolate to
the antibiotic(s) used, were available [11,12,19,20,24,31,51–
53]. Of the isolates, 132 produced a VIM-type MBL and 102
were KPC-positive. Two hundred and ﬁfteen patients had BSIs
(primary, secondary, or intravenous catheter-related), 14 had
pneumonia, and the remaining ﬁve had other infections.
Among the 234 patients included in the analysis, 111 (47.5%)
received monotherapy (one drug was active in vitro against
the infecting organism), 82 (35%) received combination ther-
apy (at least two drugs were active in vitro), and the remaining
41 (17.5%) received ‘inappropriate’ therapy (no drug was
active in vitro). It should be noted that the susceptibility to
carbapenems was taken as reported in the relevant studies, in
which the previous CLSI interpretive criteria were applied.
Monotherapy vs. combined therapy
The efﬁcacies of antimicrobial treatment regimens, as
recorded in the aforementioned studies conducted in Greece,
TABLE 3. Efﬁcacy of antimicrobial regimens used to treat
infections caused by carbapenemase-producing Klebsiella
pneumoniae
Antibiotic regimen
No. of
patients (%)
Outcome
success (%) Failure (%)
Monotherapy
Colistin 64 (24.2) 35 (54.7) 29 (45.3)
Tigecycline 8 (4.7) 5 (62.5) 3 (37.5)
Aminoglycoside 16 (6.8) 12 (75.0) 4 (25.0)
Carbapenem 23 (9.8) 18 (78.3) 5 (21.7)
Total 111 (47.5) 70 (63.1) 41 (36.9)
Combination therapy
Two or more active drugs
(carbapenem not included)
52 (22.2) 38 (73.1) 14 (26.9)
Two or more active drugs
(carbapenem included)
30 (12.8) 28 (93.3) 2 (6,7)
Total 82 (35.0) 66 (80.5) 16 (19.5)
‘Inappropriate’ therapy 41 (17.5) 23 (56.1) 18 (43.9)
Total 234 (100) 159 (67.9) 75 (32.1)
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are presented in Table 3. Monotherapy with either a carbape-
nem or an aminoglycoside (mostly gentamicin) resulted in
moderate success rates that were higher than that observed
with tigecycline, but the number of patients treated with the
latter drug was too small to allow comparisons. Colistin was
the least effective agent in the monotherapy group, as 29 of 64
colistin-treated patients were reported as having treatment
failure rates similar to that observed for the patients receiving
‘inappropriate’ therapy. Thus, the efﬁcacy of monotherapy was
not satisfactory, mainly because of the inferior activity of colis-
tin, which was used in 57.7% of the patients treated with a sin-
gle drug. The overall success rate of combination therapy was
signiﬁcantly higher than that of monotherapy (p 0.01; OR 2.41;
95% CI 1.2–4.7). The antibiotics most frequently used in com-
bination therapy, in descending order, were colistin (n = 63),
aminoglycosides (n = 46), carbapenems (n = 30), tigecycline
(n = 26), aztreonam (n = 2), and tetracyclines (n = 2). It is of
note that, on division of the patients who received combina-
tion therapy into two groups on the basis of the inclusion of a
carbapenem in the regimen, it was shown that the carbape-
nem-containing regimens were signiﬁcantly more efﬁcacious
than the non-carbapenem-containing regimens (p 0.04;
OR 5.15; 95% CI 1.1–24.5). We should nevertheless empha-
size once more that the above estimations were based on
crude data derived from various types of study without con-
trol groups for comparison.
Is there room for improvement?
The relatively high number of CPKP-infected patients treated
with a single antimicrobial agent may, in part, reﬂect a recent
trend towards monotherapy in hospital-acquired infections,
as supported by the ﬁndings of recent meta-analyses of rele-
vant studies [54,55]. However, our observations, despite
their limitations, suggest that combination schemes, especially
those including an active carbapenem, are superior to mono-
therapy in controlling serious infections caused by CPKP.
The poor performance of colistin monotherapy, as
assessed here, is a matter of concern, as the drug is among
the few drugs that are active against CPKP. Recent clinical
observations support the view that the inferior efﬁcacy of
colistin monotherapy may be associated, among other fac-
tors, with suboptimal dosing regimens of the drug [56]. The
currently administered dosing regimens of colistin result in
relatively low plasma concentrations that are unable to have
substantial bactericidal activity against the infecting organism
[57]. An additional drawback of the standard regimens may
be the delayed attainment of adequate drug concentrations.
We therefore think that it is important to administer an ini-
tial loading dose of the drug and continue treatment with an
adequate total daily dosage of colistin, in order to achieve
efﬁcacious levels according to current recommendations
[58,59]. To better exploit the therapeutic potential of colis-
tin against CPE, further studies, including pharmacokinetic/
pharmacodynamic studies and clinical trials, are needed. Not-
withstanding these issues, the ﬁndings presented herein do
not necessarily mean that the drug should be regarded as
unsuitable for the treatment of CPE infections. Indeed, the
increased numbers of successful outcomes when it was com-
bined with other active antibiotics, especially carbapenems,
may indicate in vivo synergism. These observations are in line
with the results of a previous review supporting the combi-
nation of colistin with other drugs in the treatment of KPC-
producing K. pneumoniae infections [60].
Although the small number of patients treated with
tigecycline monotherapy precludes deﬁnite conclusion as its
in vivo activity against CPKP infections, combination regimens
containing tigecycline along with one or two active drugs
resulted in satisfactory success rates. Clinicians, however,
must be aware that treatment of serious hospital infections
such as ventilator-associated pneumonias and bacteraemia
with tigecycline has been associated with an increased
risk of death [61] (http://www.fda.gov/Drugs/DrugSafety/
ucm224370.htm). The probable reasons are: (i) the fact that
tigecycline is primarily bacteriostatic against Gram-negatives;
and (ii) its low concentrations in various anatomical sites,
including serum, urine, and epithelial lining ﬂuid, which are
commonly below the MICs for CPEs [62–64]. It is therefore
necessary to determine, in clinical trials, those CPE infec-
tions that could be efﬁciently treated with tigecycline. At
present, it seems reasonable to suggest the use of this drug
as part of a combination therapy, considering the site of the
CPE infection and the MIC of the microorganism. Unpub-
lished data from Greece indicate that there is a clear trend
towards tigecycline resistance among multidrug-resistant
Gram-negatives, with c. 15% of CPKPs exhibiting MICs of
>2 mg/L.
The issue of whether carbapenems should be used in the
treatment of CPE infections is still unsettled [65]. The data
presented here, however, indicate that carbapenems provide
therapeutic beneﬁt against CPKPs exhibiting MICs up to
4 mg/L, which is closer to the EUCAST breakpoints (2012;
http://www.eucast.org). The fact that the carbapenem-con-
taining regimens were the most efﬁcacious among the combi-
nation schemes further underlines the therapeutic potential
of these antibiotics. Also, the data from animal experimental
infections summarized above, as well as from human studies
[47–49,66,67], suggest that the pharmacokinetic/pharmacody-
namic characteristics of carbapenems may allow adaptations
that could be valuable in controlling CPE infections. For
instance, the probabilities of attaining a 50% T>MIC target
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for isolates with meropenem MICs of 4 and 8 mg/L are
100% and 85%, respectively, when the drug is given in a
high-dose/prolonged-infusion scheme (3-h infusion of 2 g
every 8 h) [68].
The success rate of ‘inappropriate’ treatment schemes
was unexpectedly high. It was not feasible to reliably deﬁne
factors associated with this observation. It is possible that
catheter-related infections and non-immunocompromised
patients were over-represented in the subgroup of success-
fully treated patients.
Fosfomycin was not included in any of the studies
reviewed here. The therapeutic potential of this agent as
part of combination regimens in CPE infections, including
bacteraemia, has been discussed, but the published relevant
data are quite limited. On the basis of unpublished experi-
ence with fosfomycin, given as an adjunct in combination
schemes in a small number of patients with bacteraemia
caused by CPKP, it appears that the usefulness of the drug is
doubtful.
Measures Required for Controlling the
Spread of Carbapenemase Producers
Some CPGNs cause local outbreaks, and the detection of a
CPGN therefore often signiﬁes an imminent outbreak.
Because of the risk associated with these infections, closure
or reduced activity of high-risk units is required. Therefore,
the spread of CPGNs may incapacitate the healthcare system
and limit the ability to provide invasive procedures and
immunosuppressive therapy in a safe medical environment.
To design an effective control strategy to limit the spread
of carbapenemases, the natural history, reservoirs and trans-
mission of CPGNs have to be deﬁned in a speciﬁc setting.
The genes encoding carbapenemases are acquired in human
pathogens. Thus, they are not generated de novo in a speciﬁc
patient, but are rather acquired by the patient. For Enterobac-
teriaceae, the natural history of acquisition is the ingestion of
a CPGN and colonization of the patient’s GIT, where ampliﬁ-
cation may occur. The proportion of persons who become
colonized after ingestion of CPGNs is unknown, but this is
probably determined by multiple factors, such as the inocula
ingested, the characteristics of the bacteria ingested, the
patient’s resistance to colonization through gastric acidity,
and the normal gut microﬂora. After colonization with
CPGNs has occurred, it may persist from days to months,
and even years. Schechner et al. [9] identiﬁed ﬂuoroquino-
lone use, transfer from another healthcare facility and admis-
sion £3 months after the ﬁrst CRE isolation as predictors of
persistent CRE rectal carriage. Saidel-Odes et al. [69], who
studied CRKP carriers, found 16.1% rectal screen negativity
at 2 weeks and 33% after 6 weeks. Thus, it appears that the
median carriage time is 3 months; however, in a signiﬁcant
proportion of carriers, it may be longer. During this period
of GIT carriage of CPGNs, shedding and transmission to
other patients may take place. Moreover, transmission of
mobile genetic elements containing the carbapenamase gene
to other strains colonizing the GIT may occur, resulting in
new CPGN clones and species, which, in turn, may be the
source of new outbreaks [70–73]. In a subset of patients,
CPGNs will migrate to a clinical site, such as the urinary
tract, wounds, and medical devices, and infection will occur.
The size of the subset that develops infection probably varies
with patient and pathogen factors, as well as the characteris-
tics of the competing gut ﬂora and exposure to antibiotics.
Borer et al. [74] described a southern Israeli hospital where
a KPC outbreak was ongoing: of 464 patients identiﬁed by
surveillance cultures as being GIT carriers of CRKP, 42 sub-
sequently developed infection with a similar strain. The
investigators identiﬁed invasive procedure, diabetes mellitus,
solid tumour, tracheostomy, urinary catheter insertion and
antipseudomonal penicillin as independent risk factors for
infection among GIT carriers [74].
It is evident that, in certain regions, the spread of carba-
penemases (NDM-1 and OXA-48) occurs primarily in the
community via the faecal–oral route, either by foodborne or
waterborne transmission. As with other enteric bacteria,
waterborne outbreaks are often on a much larger scale than
foodborne epidemics. Walsh et al. [75] detected bacteria
with NDM-1 in 12 of 171 seepage samples and in two of 50
water samples in New Delhi. Indeed, NDM-1 was described
in various community-acquired infections in India [73]. OXA-
48 has been detected in patients with community-acquired
infections and among those with no contact with the health-
care setting, suggesting community acquisition via food or
water [76]. Control of the spread of carbapenemases via the
water supply has not been investigated. However, it is very
likely that improved sewage systems and their separation
from potable water, and adequate chlorination, are the main
measures required. Similarly, improved sanitation is required
where the foodborne route is suspected. It is beyond the
scope of this article to discuss control measures in areas
where spread occurs via foodborne or waterborne out-
breaks. However, in a globalized world, where travel, migra-
tion, medical tourism and trade between countries with
different levels of sanitary conditions is common, repeated
importation of CPGNs is to be expected from countries
where these bacteria spread in the community.
In contrast, in western countries with safe water systems
and better sanitation, carbapenemases are acquired almost
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exclusively in the healthcare setting. The NDM-1 and OXA-48
enzymes, which are primarily imported from overseas, where
they are acquired either in healthcare settings or in the com-
munity, may then result in nosocomial outbreaks in western
countries [77–80]. The KPC and VIM enzymes, which were
recognized initially in western countries, spread primarily in
healthcare settings; even after 15 years of ongoing nosocomial
outbreaks, community spread in western countries is still a
rare event. However, even in developed countries, large reser-
voirs of carriers have accumulated, both in acute-care and
long-term-care facilities in affected countries [13,25,81,82].
Thus, because of the large reservoirs both in healthcare
settings and in the community in certain countries, and the
lack of real-time information on the status of outbreaks, all
healthcare facilities should be ready for the importation of
CPGNs and their imminent in-hospital spread. Indeed,
recently, the European Centre for Disease Prevention and
Control (ECDC) has performed a risk assessment based on
systematic reviews on the spread of CPE through patient
transfer between healthcare facilities, with special emphasis
on cross-border transfer [83]. The conclusions from the sys-
tematic reviews in the ECDC risk assessment were that
cross-border transfer of patients from one healthcare facility
to another is a risk factor for the transmission and spread of
CPGNs into healthcare settings.
Several guidance documents on the control of CPGNs have
been published over the last 3 years. Of special note are the
documents by the US CDC [84], the ESCMID Expert Group
[1], and European national experts [85]. Although there are
some differences between these guidance documents, many
similarities and common themes are the rule. Thus, these
three documents should be read as complementing each
other. The ECDC technical report [83] provides an exhaustive
systematic review of the literature; eight intervention studies
were identiﬁed. Interventions were based on a combination of
two to seven infection control measures, which were imple-
mented. Most interventions (n = 6) combined at least active
surveillance cultures and control measures targeted at CPGN-
colonized patients, such as contact precautions and/or cohort
nursing. The results provided suggestive and consistent evi-
dence for the effectiveness of combined interventions, includ-
ing active surveillance culture for early detection of CPGN-
colonized patients, contact precautions, and cohort nursing
care for CPGN-colonized patients. Other measures have been
employed, such as antibiotic restriction, promotion of hand
hygiene and environmental surface decontamination, patient
decolonization with antiseptic bathing, and healthcare staff
education; however, their effectiveness is unclear. Environ-
mental decontamination may play a more important role in
eradicating non-fermentatives such as Acinetobacter baumannii
and P. aeruginosa, which have the ability to survive on dry sur-
faces [86,87]. The Expert Group recommended active screen-
ing of all high-risk patients, the use of additional contact
precautions, and dedicated staff/cohort nursing for all isolated
patients who are conﬁrmed carriers of CPGNs. Identifying
high-risk patients and performing active surveillance by rectal
screening of any patient transferred from a healthcare facility
in another country is essential for preventing the introduction
and transmission of CPGNs. In Israel, surveillance cultures
were implemented as an integral part of a national plan to con-
trol CPGNs. Studies from several hospitals have documented
the importance of this measure [88,89] (Table 4).
Detection, diagnosis and conﬁrmation of the presence of
carbapenemases is important for surveillance, infection con-
trol and treatment purposes. Ideally, detection of carbapene-
mases for active screening purposes should have a short
turn-around time and be available at the point of care, to
ensure timely implementation of infection control measures,
in order to effectively prevent spread. Identifying patients
who are at high risk of colonization or infection with CPGNs
and performing active screening by rectal swab on admission
to healthcare facilities is strongly advocated, and this practice
is now becoming more widespread in healthcare settings.
The implementation of more extensive active surveillance
during outbreaks is also recommended (e.g. follow-up sur-
veillance at regular time intervals and/or for all contacts with
conﬁrmed cases). To confront the risk of CPGNs, successful
infection control measures based on early detection and con-
tainment through isolation and cohorting are required.
A pro-active approach is strongly recommended [90]. This
approach assumes that allocating resources up front will allow
earlier detection and containment. Because of the logarithmic
escalation of such an outbreak, it is more cost-effective to com-
bat the problem before it has been established. The pro-active
approach aims to achieve eradication even when this is difﬁcult
and resource-consuming, and, when this is not feasible, will aim
TABLE 4. Recommended control measures for spread of
carbapenemase-producing Gram-negatives [1,84,85,88,89]
General recommendation
Improved sanitary measures in the outpatient setting
Strongly suggested
Limitation of patient transfer between healthcare facilities
Active screening of patients transferred from a high-risk institution/country
In-hospital contact precautions and cohorting for already colonized patients
Recommended, but effectiveness unclear
Application of an antibiotic stewardship programme
Restricted use of any antibiotics, particularly ﬂuoroquinolones,
broad-spectrum cephalosporins and penicillins, and carbapenems
Avoid unnecessarily long duration of antibiotic treatment
Promotion of hand hygiene
Environmental surface decontamination
Decolonization of patients with antiseptic bathing
Education of healthcare personnel
Closure or reduced activity of high-risk units
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at containment at the lowest achievable levels of spread. When
a CPGN is detected, the responsible infection control person-
nel should be immediately alerted, and a pre-prepared plan to
contain and eradicate CRGN spread should be implemented.
Only a fraction of the colonized population may be detected by
the use of clinical specimens, and patients with unrecognized
and asymptomatic colonization may serve as a reservoir for
transmission of the pathogens [25,91]. Thus, the detection of
these unrecognized carriers is essential for successful control.
The ESCMID Expert Group also recommended that all
interventions should be coordinated on a regional, national or
even international level and across the healthcare system [1].
This is supported by experience from Israel, the USA, and else-
where [92,93]. Guidelines for effective intervention must be
prepared before CPGNs have entered the region, and should
be implemented immediately upon detection of CPGNs by clin-
ical culture. Communication channels at the local, regional and
national levels should be established in advance, in order to
facilitate rapid notiﬁcation and feedback. In settings in which
the prevalence of CRE infections is low, the main goal should
be complete eradication. Screening should be performed for all
patients who have had epidemiologically signiﬁcant contact with
the index case (e.g. hospitalization on the same ward, and treat-
ment by the same staff), and epidemiological investigation
should be carried out in cases of nosocomial cross-transmis-
sion. Alerts of previously identiﬁed CPGN carriers should be
provided for every re-admitted patient. Cohorting of patients
with dedicated staff is warranted, and has been one of the main
factors in the Israeli national intervention [92].
Although control measures are expensive and may be dif-
ﬁcult to implement, if we consider the impact of associated
infections, then intensive, rigorous control programmes seem
to be justiﬁed, as early intervention has a much higher likeli-
hood of aborting an epidemic, and, in the long term, is much
less costly than confronting an epidemic. The success of the
intervention should be monitored constantly, and, when fail-
ure is observed, root-cause analysis should be performed.
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